9) Clinical Diagnosis and Management of Alzheimer's Disease

There are three primary divisions in the clinical spectrum for the diagnosis and management of AD. Signs and symptoms of the disease include cognitive impairments that occur as it progresses, effects on fluid memory, loss of cognitive domains, and crystallization of intelligence (1). There is a special section for the probable AD criterion, where substantial changes in MCI are cataloged, in the criterion of The National Institute on Aging and the Association of Central Clinical AD for All Causes of Dementia (2,3). There is a special section for the probable AD in the *National Institute on Aging* y la *Alzheimer's Association* (NIA-AA) core clinical for all causes of dementia, where significant changes in MCI are cataloged (1). Diagnosis: The main goal of treatment is an accurate and rapid diagnosis. It is required to cover at least 3 criteria of the NIA-AA diagnostic manual for the AD spectrum. Imaging, biopsies, serum tests, CFS tests, and genetic testing are performed. Is recommendable that people over the age of 70 who do not suffer from MCI involve evidence found through biomarkers or cerebral biopsies post mortem. Finally, an evaluation of the historical elements and the multidomain syndrome allows an evaluation of the syndromes associated with behavior (7). Management is classified into two types. The first type is non-pharmacological and should be used as the first-line treatment for BPSD, along with caregiver training and cognitive behavioral strategies. Changes in the patient's environment, persistence, and simple routines can also be extremely beneficial(6). Pharmacological management includes the cessation of harmful drugs (5), the treatment of comorbidities, the use of antipsychotics with extreme caution, anti-AD drugs such as cholinesterase and metamine inhibitors (donepezil, rivastigmine, galantamine, metmine) (7), and the proper handling of vitamins, supplements, and medical foods (1).

1. Sandra Weintraub, Sureyya S. Dikmen, Robert K. Heaton, David S. Tulsky, Philip D. Zelazo, Patricia J. Bauer, Noelle E. Carlozzi, Jerry Slotkin, David Blitz, Kathleen Wallner-Allen, Nathan A. Fox, Jennifer L. Beaumont, Dan Mungas, Cindy J. Nowinski, Jennifer Richler, Joanne A. Deocampo, Jacob E. Anderson, Jennifer J. Manly, Beth Borosh, Richard Havlik, Kevin Conway, Emmeline Edwards, Lisa Freund, Jonathan W. King, Claudia Moy, Ellen Witt, Richard C. Gershon, Cognition assessment using the NIH Toolbox Neurology Mar 2013, 80 (11 Supplement 3) S54-S64; DOI: 10.1212/WNL.0b013e3182872ded
2. Alireza Atri,The Alzheimer’s Disease Clinical Spectrum: Diagnosis and Management, Medical Clinics of North America,Volume 103, Issue 2, 2019, Pages 263-293,ISSN 0025-7125, ISBN 9780323654715, https://doi.org/10.1016/j.mcna.2018.10.009.
3. McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr, Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association

workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, *7*(3), 263–269. https://doi.org/10.1016/j.jalz.2011.03.005

4. Alireza Atri, Chapter 50 - Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice, Editor(s): Joseph C. Masdeu, R. Gilberto González, Handbook of Clinical Neurology, Elsevier, Volume 136, 2016, Pages 971-984, ISSN 0072-9752, ISBN 9780444534866, https://doi.org/10.1016/B978-0-444-53486-6.00050-8.
5. Campbell, N. L., Perkins, A. J., Khan, B. A., Gao, S., Farber, M. O., Khan, S., Wang, S., & Boustani, M. A. (2019). Deprescribing in the Pharmacologic Management of Delirium: A Randomized Trial in the Intensive Care Unit. *Journal of the American Geriatrics Society*, *67*(4), 695–702. https://doi.org/10.1111/jgs.15751
6. Kolanowski, A., Boltz, M., Galik, E., Gitlin, L. N., Kales, H. C., Resnick, B., Van Haitsma, K. S., Knehans, A., Sutterlin, J. E., Sefcik, J. S., Liu, W., Petrovsky, D. V., Massimo, L., Gilmore-Bykovskyi, A., MacAndrew, M., Brewster, G., Nalls, V., Jao, Y. L., Duffort, N., & Scerpella, D. (2017). Determinants of behavioral and psychological symptoms of dementia: A scoping review of the evidence. *Nursing outlook*, *65*(5), 515–529. https://doi.org/10.1016/j.outlook.2017.06.00
7. Damiana Scuteri, Maria Tiziana Corasaniti, Paolo Tonin, Pierluigi Nicotera, Giacinto Bagetta, New trends in pharmacological control of neuropsychiatric symptoms of dementia, Current Opinion in Pharmacology, Volume 61, 2021, Pages 69-76, ISSN 1471-4892, https://doi.org/10.1016/j.coph.2021.09.002.